阅读说明：本技术 一种3-芳基吡唑啉酮类化合物在制备胰脂酶抑制剂中的应用 (Application of 3-aryl pyrazolone compound in preparation of pancreatic lipase inhibitor ) 是由 鲍晓泽 杨洋 王鸿 叶欣艺 任金辉 于 2020-12-30 设计创作，主要内容包括：本发明公开了一种如式I所示的3-芳基吡唑啉酮类化合物在制备胰脂酶抑制剂中的应用,并经过结构优化发现了一个新的先导化合物23。本发明首次将3-芳基吡唑啉酮类化合物用于制备胰脂酶抑制剂,并据此发现了新的先导化合物,为开发基于脂胰酶的脂质代谢调控靶标药物提供潜在选择。(The invention discloses application of a 3-aryl pyrazolone compound shown as a formula I in preparation of a pancreatic lipase inhibitor, and a new lead compound 23 is discovered through structural optimization. The invention firstly uses the 3-aryl pyrazolone compound to prepare the pancreatic lipase inhibitor, and finds a new lead compound according to the preparation method, thereby providing a potential choice for developing a lipid metabolism regulation target drug based on lipopancreatin.)

1. An application of 3-aryl pyrazolone compounds shown in formula (I) in preparing pancreatic lipase inhibitor,

in the formula (I), R is C1-C3 alkyl and phenyl; the R is¹Is phenyl, halogen monosubstituted phenyl, C1-C3 alkyl substituted phenyl, C1-C3 alkoxy substituted phenyl, 2-thienyl, 1-naphthyl or 2-naphthyl; the R is²Is C1-C3 alkyl, vinyl, 2-thienyl, 2-furyl, 1-naphthyl, 2-naphthyl, benzene2-nitrophenyl, halogen mono-substituted phenyl, 4-trifluoromethylphenyl, 3, 5-ditrifluoromethylphenyl, C1-C3 alkyl substituted phenyl, C1-C3 alkoxy substituted phenyl; the halogen is fluorine, chlorine or bromine.

2. The use according to claim 1, wherein R is methyl, phenyl; the R is¹Is phenyl, 2-fluorophenyl, 3-methylphenyl, 4-methylphenyl, 2-naphthyl and 2-thienyl; the R is²Is methyl, ethyl, vinyl, 2-thienyl, 2-furyl, phenyl, 2-nitrophenyl, 2-chlorophenyl, 4-bromophenyl, 4-fluorophenyl, 4-trifluoromethylphenyl, 3, 5-bistrifluoromethylphenyl, 2-methylphenyl, 3-methylphenyl, 4-methoxyphenyl or 1-naphthyl.

3. Use according to claim 1, characterized in that the 3-arylpyrazolone compound of formula (I) is one of the following:

4. a compound 23 for use according to claim 1,

5. compound 23 according to claim 4, characterized in that said compound 23 is prepared by a process comprising:

(1) dissolving the compound 24, dimethyl carbonate and sodium hydride in toluene, and reacting at 120 ℃ to prepare a compound 25;

(2) dissolving the compound 25, 2-thiophenecarboxaldehyde, glacial acetic acid and tetrahydropyrrole in toluene, and reacting at 120 ℃ to prepare a compound 26;

(3) dissolving the compound 26 and sodium borohydride in pyridine, and reacting at room temperature to prepare a compound 27;

(4) carrying out reflux reaction on the compound 27 and phenylhydrazine at 120 ℃, and recrystallizing to prepare a compound 23;

6. compound 23 according to claim 4, characterized in that said compound 23 is prepared by the following steps:

1) at room temperature, adding dimethyl carbonate and toluene in a two-mouth bottle provided with a constant-pressure dropping funnel and a reflux condensing device, fully stirring, adding NaH in batches, and heating to 120 ℃; then, dropwise adding a compound 24 toluene solution with the mass concentration of 34%, and stirring for 30 minutes after the dropwise adding is finished; cooling the reaction system to room temperature, and adding ice water in an ice bath for quenching; then, regulating the pH value to be between 5 and 6 by using 3M hydrochloric acid, extracting by using ethyl acetate, combining ethyl acetate phases, drying by using anhydrous sodium sulfate, and concentrating until no liquid is evaporated out to obtain a yellow oily substance, namely a compound 25;

2) adding a compound 25 and toluene a into a round-bottom flask provided with a water separator and a condenser at room temperature, stirring, then adding 2-thiophenecarboxaldehyde, glacial acetic acid and tetrahydropyrrole, adding toluene b into the water separator, heating to 135 ℃, and reacting for 6-12 h; petroleum ether in a volume ratio of 20: 1: monitoring by TLC with ethyl acetate as a developing agent, adding water to quench the reaction after the reaction is finished, extracting with ethyl acetate, combining ethyl acetate phases, drying with anhydrous sodium sulfate, concentrating until no liquid is evaporated, and performing TLC detection by using ethyl acetate as a developing agent according to a volume ratio of 20:1 petroleum ether/ethyl acetate as eluent, and performing silica gel column chromatography by using petroleum ether: monitoring by TLC with ethyl acetate as a developing agent, collecting components with Rf value of 0.2-0.3, and concentrating to dryness to obtain a compound 26;

3) adding compound 26 and pyridine into a round-bottom flask, then adding sodium borohydride, magnetically stirring for 2 hours at room temperature, adding 2M hydrochloric acid to quench the reaction, extracting with ethyl acetate, extracting the water phase with ethyl acetate, combining the ethyl acetate phases, drying with anhydrous sodium sulfate, concentrating until no liquid is evaporated, and adding the mixture of the compounds in a volume ratio of 20:1 petroleum ether/ethyl acetate as eluent, and performing silica gel column chromatography by using petroleum ether: monitoring TLC with ethyl acetate as developing agent, collecting components with Rf value of 0.2-0.3, concentrating until no liquid flows out to obtain compound 27;

4) adding the compound 27 and phenylhydrazine into a round-bottom flask at normal temperature, heating to 120 ℃, stirring and refluxing for reaction, and reacting the mixture in a volume ratio of 20:1 petroleum ether: monitoring by TLC with ethyl acetate as developing agent; after the reaction is finished, adding ethanol, cooling to 90 ℃, and recrystallizing to obtain crystals, wherein the volume ratio of the obtained crystals is 20:1 petroleum ether/ethyl acetate as eluent, and performing silica gel column chromatography by using petroleum ether: and (3) performing TLC monitoring by using ethyl acetate as a developing agent, collecting components with Rf value of 0.2-0.3, and concentrating to dryness to obtain a compound 23.

7. The compound 23 of claim 6, wherein in step 1) the ratio of the amount of compound 24 to dimethyl carbonate material is 1: 1-3; the amount of compound 24 and NaH substance is prepared to be 1: 1-3; the total volume of toluene used was 1.5mL/mmol based on the amount of compound 24.

8. The compound 23 of claim 6, wherein the ratio of the amount of compound 25 to 2-thiophenecarboxaldehyde in step 2) is from 1:1 to 2; the amount ratio of the compound 25 to the glacial acetic acid substance is 1: 0.1-1; the amount ratio of the compound 25 to the tetrahydropyrrole substance is 1: 0.1-1; the volume of the toluene a is 3mL/mmol based on the amount of the compound 25; the volume of the toluene a is 1mL/mmol based on the amount of the compound 25.

9. The compound 23 of claim 6, wherein the ratio of the amount of compound 26 to the amount of sodium borohydride material in step 3) is 1: 1-2; the volume usage of the pyridine is 3-5mL/mmol based on the mass of the compound 26; the amount ratio of the compound 27 to the phenylhydrazine substance in the step 4) is 1: 1-2.

10. Use of a 3-arylpyrazolone compound of formula (I) according to claim 1 in the preparation of a medicament for the treatment of obesity.

Technical Field

The invention relates to an application of 3-aryl pyrazolone compounds in preparation of pancreatic lipase inhibitors, belonging to the technical field of fine organic chemistry and biomedicine.

Background

In recent years, with the accelerating aging of population and the change of life style, the incidence rate of overweight and obesity in China is rapidly increased, and the country with the fastest incidence rate of overweight and obesity is formed. Chinese resident nutrition and health condition monitoring reports (2010-2013) show that the prevalence rate of overweight, obesity and central obesity of adults in China is 32.4%, 13.2% and 45.2%. The factors affecting obesity are complex and various, and are often accompanied by triglyceride, cholesterol, and higher than normal blood pressure levels. Studies have shown that abnormal metabolism of esters such as triglycerides and cholesterol can significantly increase the risk of development of diseases such as atherosclerosis and type II diabetes [ l.menegaut, c.thomas, l.lagrost, d.masson, CurrOpin Electrochem,2017,28,19-26 ]. Therefore, around the key targets of lipid synthesis, transport, metabolism and storage, the development of effective drugs that can regulate lipid metabolism is an important direction for the prevention and treatment of metabolic diseases.

Pancreatic Lipase (PL) enables humans to ingest Triglycerides (TG) from food. Dietary fat, particularly TG containing 12-18 carbon fatty acids, is hydrolyzed mainly by PL into monoacylglycerols and free fatty acids, and is absorbed by small intestinal epithelial cells, and then synthesized again in vivo. Research shows that the inhibition of PL activity can result in the inhibition of fat hydrolysis and absorption in human body, and is favorable to the auxiliary treatment of obesity, type 2 diabetes, hypertension, hyperglycemia, hyperlipidemia and other diseases.

Pyrazolones are a very important class of backbone in pharmaceuticals and active compounds, such as the drugs edaravone, aminopyrine, etc. Because of easy synthesis and convenient structure modification, the development of the application of the skeleton in the treatment of diseases is also a hot point of research in the field of medicinal chemistry at present. Therefore, the development of a pancreatic lipase inhibitor based on a pyrazolone skeleton, which is easy to synthesize, can be used as a lead compound to provide a basis for the development of related medicaments.

Disclosure of Invention

The invention aims to provide a 3-aryl pyrazolone compound and application thereof in preparing a pancreatic lipase inhibitor, and the compound has potential application prospect in the aspect of combined medication with a hypolipidemic drug.

The technical scheme adopted by the invention is as follows:

in a first aspect, the invention provides the use of a 3-arylpyrazolone compound of formula (I) in the preparation of a pancreatic lipase inhibitor, the structural formula of which is as follows:

in the formula (I), R is C1-C3 alkyl and phenyl; the R is¹Is phenyl, halogen monosubstituted phenyl, C1-C3 alkyl substituted phenyl, C1-C3 alkoxy substituted phenyl, 2-thienyl, 1-naphthyl or 2-naphthyl, etc.; the R is²Is C1-C3 alkyl, vinyl, 2-thienyl, 2-furyl, 1-naphthyl, 2-naphthyl, phenyl, 2-nitrophenyl, halogen monosubstituted phenyl, 4-trifluoromethylphenyl, 3, 5-bistrifluoromethylphenyl, C1-C3 alkyl substituted phenyl, C1-C3 alkoxy substituted phenyl; the halogen is fluorine, chlorine or bromine.

Further, preferably, R is methyl, phenyl; the R is¹Is phenyl, 2-fluorophenyl, 3-methylphenyl, 4-methylphenyl, 2-naphthyl and 2-thienyl; the R is²Is methyl, ethyl, vinyl, 2-thienyl, 2-furyl, phenyl, 2-nitrophenyl, 2-chlorophenyl, 4-bromophenyl, 4-fluorophenyl, 4-trifluoromethylphenyl, 3, 5-bistrifluoromethylphenyl, 2-methylphenyl, 3-methylphenyl, 4-methoxyphenyl or 1-naphthyl.

Further, it is preferable that the 5-pyrazolone compound represented by the formula (I) is one of the following:

in a second aspect, the present invention provides a 3-arylpyrazolone compound represented by formula (23), wherein the preparation of compound 23 is performed according to the following steps:

(1) preparing a compound shown as a formula 25 by reacting a compound shown as a formula 24 with dimethyl carbonate and sodium hydride in toluene according to a molar ratio of 1:1-3:1-3 at 120 ℃;

(2) preparing a compound shown as a formula 26 from the compound shown as the formula 25, 2-thiophenecarboxaldehyde, glacial acetic acid and tetrahydropyrrole in toluene according to a molar ratio of 1:1-2:0.1-1:0.1-1 at 120 ℃;

(3) preparing a compound shown as a formula 27 from a compound shown as a formula 26 and sodium borohydride in pyridine according to a molar ratio of 1:1-2 at room temperature;

(4) carrying out reflux reaction on the compound shown in the formula 27 and phenylhydrazine at 120 ℃ according to the molar ratio of 1:1-2, and recrystallizing to prepare a compound shown in a formula 23;

further, compound 23 was prepared as follows:

1) adding dimethyl carbonate and toluene into a two-mouth bottle provided with a constant-pressure dropping funnel and a reflux condensing device at room temperature, fully stirring, adding NaH (preferably 4 times) in batches, and heating to 120 ℃; then dropwise adding a toluene solution of 2-acetonaphthone (24) with the mass concentration of 34%, and stirring for 30 minutes after the dropwise adding is finished; cooling the reaction system to room temperature, and adding ice water in an ice bath for quenching; then, regulating the pH value to be between 5 and 6 by using 3M hydrochloric acid, extracting by using ethyl acetate (20mL multiplied by 3), combining ethyl acetate phases, drying by using anhydrous sodium sulfate, concentrating until no liquid is evaporated out to obtain yellow oily liquid, namely methyl 3-naphthalene-3-oxopropionate (25), and directly using the yellow oily liquid in the next reaction; the amount ratio of the 2-acetonaphthone (24) to the dimethyl carbonate is 1:1-3, preferably 1: 2.5; the amount of 2-acetonaphthone (24) and sodium hydride material is prepared to be 1:1-3, preferably 1: 2.5; the total volume dosage of the toluene is 1.5mL/mmol based on the amount of the 2-acetonaphthone (24) substance;

2) adding methyl 3-naphthalene-3-oxopropionate (25) and toluene a into a round-bottom flask provided with a water separator and a condenser at room temperature, stirring, then adding 2-thiophenecarboxaldehyde, glacial acetic acid and tetrahydropyrrole, adding toluene b into the water separator, heating to 135 ℃, and reacting for 6-12 h; after completion of the reaction, the reaction was quenched by addition of water and extracted with ethyl acetate (20mL × 3), and the ethyl acetate phases were combined, dried over anhydrous sodium sulfate, concentrated to no liquid and distilled off in a volume ratio of 20: performing silica gel column chromatography with petroleum ether/ethyl acetate as eluent, monitoring by TLC (developing solvent is petroleum ether: ethyl acetate: 20:1, v/v), collecting components with Rf value of 0.2-0.3, and concentrating to dryness to obtain yellow solid 26; the ratio of the amount of methyl 3-naphthalene-3-oxopropionate (25) to the amount of 2-thiophenecarboxaldehyde species is 1:1-2, preferably 1: 1; the ratio of the amount of methyl 3-naphthalene-3-oxopropionate (25) to the amount of glacial acetic acid substance is 1:0.1-1, preferably 1: 0.1; the ratio of the amount of methyl 3-naphthalene-3-oxopropionate (25) to the amount of tetrahydropyrrole substance is 1:0.1 to 1, preferably 1: 0.1; the volume usage amount of the toluene a is 3mL/mmol based on the amount of the 3-naphthalene-3-oxopropionic acid methyl ester (25) substance; the volume dosage of the toluene a is 1mL/mmol based on the amount of the 3-naphthalene-3-oxopropionic acid methyl ester (25) substance; toluene a and toluene b are both toluene and are named for distinguishing the difference of the addition amount of different steps, and the letter has no meaning per se;

3) adding compound 26 and pyridine into a round-bottom flask, then adding sodium borohydride, magnetically stirring for 2 hours at room temperature, adding 2M hydrochloric acid to quench the reaction, extracting with ethyl acetate, extracting the water phase with ethyl acetate, combining the ethyl acetate phases, drying with anhydrous sodium sulfate, concentrating until no liquid is evaporated, and adding the mixture of the compounds in a volume ratio of 20: performing silica gel column chromatography with petroleum ether/ethyl acetate as eluent, monitoring by TLC (developing agent is petroleum ether: ethyl acetate: 20:1, v/v), collecting components with Rf value of 0.2-0.3, and concentrating to dryness to obtain colorless oily liquid 0.9g, namely compound 27; the amount ratio of the compound 26 to the sodium borohydride material is 1: 1-2; the volume usage of the pyridine is 3-5mL/mmol based on the mass of the compound 26;

4) adding compound 27 and phenylhydrazine into a round-bottom flask at normal temperature, heating to 120 ℃, stirring and refluxing for reaction, and performing TLC (a developing solvent is petroleum ether: ethyl acetate ═ 20: 1) monitoring the reaction process; after the reaction is finished, adding ethanol, cooling to 90 ℃, and recrystallizing to obtain crystals, wherein the volume ratio of the obtained crystals is 20: performing silica gel column chromatography with petroleum ether/ethyl acetate as eluent, monitoring by TLC (a developing agent is petroleum ether and ethyl acetate of 20:1, v/v), collecting components with Rf of 0.2-0.3, and concentrating to dryness to obtain a product 23; the amount ratio of the compound 27 to the phenylhydrazine substance is 1: 1-2.

The invention also provides application of the 3-arylpyrazolone compound shown in the formula (I) in preparation of weight-reducing drugs, and provides a potential choice for developing PL-based lipid metabolism regulation target drugs.

Compared with the prior art, the invention has the following beneficial effects: the invention firstly uses the 3-aryl pyrazolone compound for preparing the pancreatic lipase inhibitor, and finds out that a new lead compound 23(IC50 value is 0.34, has equivalent effect with the existing obesity-reducing drug Oslittat (IC50 value is 0.19) with more side effects on the market, and is expected to provide potential selection in developing novel weight-reducing drugs with less side effects.

Drawings

FIG. 1 is a graph showing the inhibition curve of compound 23 against lipopancreatin (PL) (ordinate: lipopancreatin residual activity; abscissa: inhibitor concentration).

FIG. 2 is a TLC monitor of Compound 26.

FIG. 3 is a TLC monitor chart of Compound 23.

FIG. 4 is a drawing of Compound 26¹H NMR chart.

FIG. 5 is a drawing of Compound 23¹H NMR chart.

Detailed Description

The present invention will be further explained with reference to specific examples, which are not intended to limit the present invention in any way. Unless otherwise indicated, the reagents and methods referred to in the examples are those commonly used in the art.

Among them, compounds 1 to 22 are known compounds reported in the literature and synthesized according to literature procedures (F.Risitano, G.Grassi, F.Caruso, F.Foti, Tetrahedron,1996,52,1443-

The room temperature of the invention is 25-30 ℃.

Example 1: preparation of lead compound 1-phenyl-3-naphthyl-4-thiophenemethyl-pyrazolone 23

(1) Preparation of Compound 26

1) 4.2mL of dimethyl carbonate (0.05mol) and 20mL of toluene were added to a 50mL two-necked flask equipped with a constant-pressure dropping funnel and a reflux condenser at room temperature, and stirred well. 2.0 g of NaH (0.05mol) were added in 4 portions, 0.5g each time, and the temperature was raised to 120 ℃. Then 10mL of a toluene solution of 34% by mass of 2-acetonaphthone (24, 2-acetonaphthone content: 20mmol) was added dropwise. After the addition was completed, the mixture was stirred for 30 minutes. The reaction was cooled to room temperature and quenched by the addition of ice water (about 20mL) in an ice bath. Then, adjusting the pH value to be between 5 and 6 by using 3M hydrochloric acid, extracting by using ethyl acetate (20mL multiplied by 3), combining ethyl acetate phases, drying by using anhydrous sodium sulfate, concentrating until no liquid is evaporated out, and obtaining yellow oily matter, namely 4.5g of methyl 3-naphthalene-3-oxopropionate (25), which is directly used for the next reaction.

2) 2.2828g of methyl 3-naphthalene-3-oxopropionate (25, 10mmol) and 30mL of toluene were placed in a 100mL round-bottomed flask equipped with a trap and condenser and stirred at room temperature, followed by 0.9mL (10 mmol) of 2-thiophenecarboxaldehyde, 0.06mL (1mmol) of glacial acetic acid and 0.08mL (1mmol) of tetrahydropyrrole and 10mL of toluene were added to the trap and heated to 135 ℃ for 12 h. Monitored by TLC (the developing solvent is petroleum ether: ethyl acetate ═ 20:1, v/v), after the reaction is finished, water is added to quench the reaction, and ethyl acetate is usedThe ester (20mL × 3) was extracted, the ethyl acetate phases were combined, dried over anhydrous sodium sulfate, concentrated to no liquid and distilled off in a volume ratio of 20:1, silica gel column chromatography using petroleum ether/ethyl acetate as eluent, monitored by TLC (developing solvent: petroleum ether: ethyl acetate 20:1, v/v), fractions with Rf value of 0.2-0.3 were collected (fig. 2), concentrated to dryness to give yellow solid 26(2.4g) in 71.2% mass yield.¹The H NMR chart is shown in FIG. 4.

¹H NMR(600MHz,CDCl₃)δ8.45(s,1H),8.15(s,1H),8.13(dd,J＝8.6,1.7Hz,1H),7.93 (dd,J＝8.6Hz,1.7Hz,2H),7.88(d,J＝8.0Hz,1H),7.61(ddd,J＝8.2,6.9,1.2Hz,1H),7.53 (ddd,J＝8.1,7.0,1.2Hz,1H),7.36-7.31(m,1H),7.31-7.28(m,1H),6.95(dd,J＝5.0,3.8Hz, 1H),3.74(s,3H)；¹³C NMR(151MHz,CDCl₃)δ195.2,165.7,136.2(2C),135.2,134.1,133.5, 132.6,131.9,131.6,129.9,129.0,128.9,127.9,127.8,126.7,124.1,52.6。

(2) Preparation of Compound 23

1) In a 50mL round bottom flask was added 1.2121g of compound 26(3.76mmol), 0.1565g (4.1mmol) of sodium borohydride and 13mL of pyridine, and the mixture was magnetically stirred at room temperature for 2h, followed by addition of 2M hydrochloric acid (20mL) to quench the reaction and extraction with ethyl acetate, extraction of the aqueous phase with ethyl acetate, combination of the ethyl acetate phases, drying over anhydrous sodium sulfate, concentration until no liquid evaporated off, and distillation at a volume ratio of 20:1, performing silica gel column chromatography by using petroleum ether/ethyl acetate as an eluent, monitoring the reaction process by TLC (a developing agent is petroleum ether and ethyl acetate is 20: 1), collecting a component (shown in figure 3) with the Rf value of 0.2-0.3, concentrating until no liquid flows out to obtain 0.9g of colorless oily substance, namely the compound 27, and directly performing the next reaction;

2) to a 50mL round-bottom flask, 1.22g of Compound 27(3.76mmol) and 0.447g (4.136mmol) of phenylhydrazine were added at room temperature, and the mixture was heated to 120 ℃ and stirred under reflux, TLC (developing solvent petroleum ether: ethyl acetate ═ 20:1, v/v) the progress of the reaction is monitored. After the reaction is finished, adding20mL of ethanol, cooling to 90 ℃ and recrystallizing to obtain a crystal, namely a product mother liquor (0.4g), wherein the volume ratio of the product mother liquor to the volume ratio of 20:1, performing silica gel column chromatography by using petroleum ether/ethyl acetate as an eluent, monitoring the reaction process by TLC (a developing agent is petroleum ether: ethyl acetate: 20: 1), collecting components with the Rf value of 0.2-0.3, and concentrating to dryness to obtain a product 23 (0.08g) with the mass yield of 31.6%. The TLC chart is shown in figure 3,¹the H NMR chart is shown in FIG. 5.

¹H NMR for enol form(400MHz,DMSO-d₆)δ11.25(s,1H),8.11(s,1H),8.01-7.86(m, 5H),7.84(d,J＝8.5Hz,1H),7.60-7.46(m,4H),7.33(s,1H),7.26(d,J＝5.7Hz,1H),6.91(dd,J ＝4.9,3.5Hz,1H),6.88(s,1H),4.27(s,2H).；¹³C NMR(151MHz,DMSO-d₆)δ151.4,148.9, 145.5,139.3,133.3,132.8,131.9,129.5,128.5,128.2,128.0,127.4,126.8,126.6,126.4,126.1, 125.6,124.8,124.3,122.0,119.1,99.7,23.3；HRMS(ESI)m/z Calcd.for C₂₄H₁₉N₂OS([M+H]⁺) 383.1213,Found 383.1205.

Example 2 evaluation of inhibition of pancreatic Lipase Activity

1. Inhibition of pancreatic lipase activity by Compound 23

(1) Pancreatic (porcine) lipase (purchased from Sigma-Aldrich, Cas 8049-47-6) was diluted to 1.0mg/mL with 0.1M citrate-disodium hydrogen phosphate buffer (pH 7.4) and placed on ice plates for use to avoid inactivation.

(2) Preparing a pancreatic lipase metabolic reaction system: 194. mu.L of citric acid-disodium hydrogenphosphate buffer (0.1M) and 2. mu.L of pancreatic lipase (1.0mg/mL) at pH 7.4;

(3) adding 2 μ L of DMSO solutions of compound 23 at different concentrations (0.00, 0.01, 0.05, 0.10, 0.50, 1.00, 5.00, 10.00, 20.00, 30.00 μ M) to the reaction system, shaking vigorously, and incubating at 37 deg.C for 10 min;

(4) adding 2 μ L of probe substrate 4-methylumbelliferone oleate (4-MUO) DMSO solution with concentration of 1.0mM, placing into enzyme-labeling instrument at 37 deg.C, and continuously detecting for 30 min; IC50 values were obtained by control with blanks (DMSO) and fitting with Prins 6.0, and the results are shown in table 1. (Note: three replicates per sample concentration)

2. Inhibition of lipopancreatin activity by Compound 1-Compound 22

Compound 23 was replaced with compound 1-compound 22 and orlistat in step 1, the other procedures were the same and the results are shown in table 1. The compound 23 has excellent inhibitory effect on lipopancreatin, and is close to the commercially available drug orlistat.

TABLE 1 inhibition of lipopancreatin activity by 3-arylpyrazolones